Oligomerix, Inc., a New York, NY-based biopharmaceutical company, completed a $2.8m Series B financing.
Investors were not disclosed.
Founded in 2006 and led by James Moe, Ph.D., MBA, president and CEO, Oligomerix develops disease modifying therapeutics for Alzheimer’s disease (AD) and related neurodegenerative disorders. The company is focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity.
It is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.
The company intends to use the funds to advance its small molecule inhibitors.